Contract Research Organizations in the US: Market Size, Businesses & Forecast 2026

The Contract Research Organizations (CRO) industry in the US consists of specialized companies providing outsourced research, preclinical testing, and clinical trial management services to the pharmaceutical, biotechnology, and medical device sectors. The industry is expanding globally and domestically, driven by complex clinical trial requirements and high outsourcing rates among drug sponsors. This momentum is evident in the financial performance of major operators, with IQVIA Holdings Inc. reporting full-year 2025 global revenue of $16,323 million (IQVIA Holdings Inc. Form 10-K, 2026) and Fortrea Holdings Inc. posting $2,723.4 million in annual revenue for the same year (Fortrea Holdings

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Contract Research Organizations in the US industry cover?

The contract research organizations industry encompasses establishments primarily engaged in providing outsourced research and experimental development services in the life sciences, medical fields, and pharmaceutical sectors. These entities manage or support critical phases of drug and device development, ranging from early-stage laboratory research to large-scale multi-site human clinical trials. They offer specialized capabilities such as biostatistics, protocol design, patient recruitment, clinical data management, regulatory affairs, and post-market safety surveillance.

• •Covers pre-clinical animal testing, toxicology, and Phase I through Phase IV human clinical trial management.
• •Categorized under NAICS code 541714 (Biotechnology Research and Development Laboratories) or NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences) depending on specific core laboratory orientations.
• •Services eliminate the need for pharmaceutical sponsors to maintain expensive internal trial infrastructure and specialized investigator networks.

Who operates in the industry and how is it structured?

The US CRO market is structured around a combination of scaled multinational corporations capable of managing complex global clinical programs and smaller, boutique firms focusing on niche therapeutic areas or localized regional testing sites. Major public and private players dominate market share by revenue, utilizing extensive clinical site networks that span dozens of countries to accelerate enrollment. The commercial relationship relies heavily on contracted backlogs and performance metrics like book-to-bill ratios to project future revenue streams.

• •Operators maintain dedicated divisions for Research & Development Solutions and Technology & Analytics Solutions.
• •Revenue visibility is determined by multi-year contracted backlogs, such as IQVIA's $32.7 billion backlog or Fortrea's $7.7 billion backlog reported at the end of 2025.
• •The market exhibits a moderate-to-high concentration among the top global players, though hundreds of regional laboratories provide localized competition.

What drives demand in the industry?

Demand for CRO services is tied closely to the total volume of active research pipelines and global spending on pharmaceutical and biotechnology research and development. The increasing clinical trial design complexity, notably within therapeutic fields like oncology and rare diseases, acts as a primary catalyst for outsourcing. Drug developers look to CROs to leverage specialized expertise in adaptive trial designs, biomarker-stratified patient selection, and sophisticated biostatistics.

• •Driven by global pharmaceutical R&D investments that exceeded $244 billion according to trade data, with an estimated outsourcing rate over 60% for clinical activities.
• •Oncology continues to be a top therapeutic driver, accounting for a leading share of active pipelines due to complex immunotherapy protocols.
• •The sheer volume of open trials, with hundreds of thousands of active studies logged on ClinicalTrials.gov, creates continuous demand for site monitoring and data validation.

Who are the notable companies in the industry?

Competition in the US CRO industry centers on global delivery scale, depth of therapeutic experience, technological capabilities, and data asset access. Major public providers report high-volume booking and distinct capital allocations to maintain localized testing facilities and clinical project managers. These multi-billion dollar enterprises frequently engage in targeted mergers and acquisitions to expand their geographic reach or add digital healthcare monitoring capabilities.

• •IQVIA Holdings Inc. is a major public market participant, reporting total global revenue of $16,323 million and an R&D solutions book-to-bill ratio of 1.18x in the fourth quarter of 2025.
• •Fortrea Holdings Inc. operates as a prominent standalone public CRO following its corporate spin-off, capturing $2,723.4 million in total full-year 2025 revenue.
• •Medpace Holdings, Inc. and ICON plc represent other leading multinational operators providing end-to-end clinical development and regulatory strategy capabilities across US sites.
• •Charles River Laboratories International, Inc. represents a crucial competitor specializing in the early-stage, pre-clinical, and laboratory-based outsourcing segments.

What are the recent trends and outlook?

The industry is adapting to macroeconomic shifts and post-pandemic normalization of clinical testing protocols, leading to an increased adoption of decentralized clinical trials (DCTs) and hybrid formats. Incorporating artificial intelligence, remote patient monitoring devices, and advanced data analytics has accelerated trial timelines and enhanced patient compliance tracking. While some operators recorded non-cash asset adjustments in early 2025 due to changing capital markets, booking activity strengthened significantly heading into 2026.

• •A second-half recovery in 2025 net bookings led to healthy leading book-to-bill metrics, positioning the sector for ongoing revenue expansion in 2026.
• •Widespread integration of predictive AI models helps optimize investigator site selection and patient enrollment models.
• •Industry margins are stabilizing as providers implement aggressive cost-savings initiatives to counter recent localized wage inflation for specialized clinical trial monitors.

How is the industry regulated?

The CRO industry operates within a highly rigid regulatory framework mandated by federal agencies to protect human subject safety and ensure the integrity of scientific data. In the United States, the Food and Drug Administration (FDA) oversees all aspects of clinical trial execution, necessitating strict adherence to Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) codes. CROs are subject to routine and unannounced agency inspections, where compliance failures can lead to project delays, data rejection, or formal warning letters.

• •All trials must align with the Federal Food, Drug, and Cosmetic Act and specific institutional review board (IRB) mandates.
• •Compliance with international standards, such as the International Council for Harmonisation (ICH) guidelines, is required for multi-country clinical registrations.
• •Data management practices must comply with stringent electronic record mandates, including FDA 21 CFR Part 11 and relevant patient privacy legislation.

Government, statistical and trade sources used for this Claight analysis.

• U.S. Securities and Exchange Commission (SEC) Filings ·
• IQVIA Holdings Inc. Annual Report (Form 10-K) 2025 ·
• Fortrea Holdings Inc. Annual Report (Form 10-K) 2025 ·
• U.S. Census Bureau NAICS Definitions ·
• U.S. Food and Drug Administration (FDA) Regulations